Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

AIFFBullishCorporate Developmentsnews

High materiality7/10

Firefly-NeuroSigma Partnership Extends AI-Driven ADHD Therapy via Monarch eTNS

Sep 25, 2026, 2:38 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Partnership enhances AIFF's growth narrative in a high-demand pediatric ADHD niche; stock already reacted positively, suggesting near-term upside but limited visibility on revenue timing given deployment timeline.

AI summary

What happened, with direct paths to the underlying reporting

Firefly Neuroscience and NeuroSigma joined forces to broaden U.S. access to the Monarch eTNS non-drug ADHD therapy, leveraging Firefly's AI-powered Evoke platform. The collaboration signals potential near-term traction as Monarch expands sales and financing options, supported by biomarker insights from Evoke. The stock moved higher on the news, underscoring a market view of initial revenue upside and broader adoption.

Firefly collaborates with NeuroSigma to expand Monarch eTNS ADHD therapy nationwide.
Evoke AI adds EEG/ERP analytics using a 200k-brain-scan database.
March 2026 biomarkers may differentiate ADHD presentations (inattentive, hyperactive, combined).
Monarch eTNS second-gen launched July 2026; waitlist >1,500; financing options expanded.
AIFF stock rose ~42% to $1.68 on Friday amid the news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Firefly-NeuroSigma Partnership Extends AI-Driven ADHD Therapy via Monarch eTNS

Firefly Neuroscience Reports Massive Growth in EEG/ERP Scan Volumes

Crude Oil Down 1%; Firefly Neuroscience Shares Spike Higher